Pfizer (PFE) Retained Earnings (2009 - 2026)
Pfizer (PFE) posted quarterly Retained Earnings of $94.8 billion for Q1 2026, up 1204.45% year-over-year from $7.3 billion in Q1 2025, and up 1274.53% quarter-over-quarter from -$8.1 billion in Q4 2025.
Pfizer (PFE) Retained Earnings (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Retained Earnings for 18 consecutive years, with $94.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 1204.45% year-over-year to $94.8 billion; the TTM figure through Mar 2026 stood at $94.8 billion (up 1204.45% YoY), while the FY2025 annual figure was -$8.1 billion, down 106.91% from the prior year.
- Retained Earnings climbed to $94.8 billion in Q1 2026 per PFE's latest filing, from -$8.1 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $128.8 billion in Q3 2023 and bottomed at -$8.6 billion in Q1 2025.
- Historically, Retained Earnings has averaged $52.7 billion across 5 years, with a median of $92.6 billion in 2023.
- On a YoY basis, Retained Earnings climbed as much as 1303.34% in 2025 and fell as far as 109.23% in 2025.
- Pfizer's Retained Earnings stood at -$8.3 billion in 2022, then surged by 1215.5% to $92.6 billion in 2023, then advanced by 26.01% to $116.7 billion in 2024, then sank by 106.91% to -$8.1 billion in 2025, then surged by 1274.53% to $94.8 billion in 2026.
- Business Quant data shows PFE's Retained Earnings at $94.8 billion in Q1 2026, -$8.1 billion in Q4 2025, and -$8.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.33 Bn | 630.58 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 469.67 Bn | 463.10 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 374.13 Bn | 366.99 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 302.76 Bn | 295.07 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.15 Bn | 252.25 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 236.76 Bn | 222.77 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 182.54 Bn | 179.36 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 105.99 Bn | 101.83 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Sanofi | 55.15 Bn | 47.77 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 112.09 Bn |
| Mar 29, 2026 | 94.77 Bn |
| Dec 31, 2025 | -8.07 Bn |
| Sep 28, 2025 | -8.07 Bn |
| Jun 29, 2025 | 94.05 Bn |
| Mar 30, 2025 | -8.58 Bn |
| Dec 31, 2024 | 116.73 Bn |
| Sep 29, 2024 | -7.97 Bn |
| Jun 30, 2024 | -7.82 Bn |
| Mar 31, 2024 | 93.00 Bn |
| Dec 31, 2023 | 92.63 Bn |
| Jul 2, 2023 | 128.80 Bn |
| Apr 2, 2023 | -8.29 Bn |
| Dec 31, 2022 | -8.30 Bn |
| Jul 3, 2022 | 116.61 Bn |
| Apr 3, 2022 | 111.19 Bn |
| Dec 31, 2021 | 103.39 Bn |
| Oct 3, 2021 | -5.65 Bn |
| Jul 4, 2021 | 89.34 Bn |
| Apr 4, 2021 | 95.16 Bn |